Home » Newsletters » BioWorld Science

BioWorld Science

April 21, 2006

View Archived Issues

Studies assess pharmacodynamics, mechanism of action of ceftobiprole

Studies assess cancer prevention with selenium compounds

Schering-Plough selects compound for metabolic disease from collaboration

Reata licenses tricyclic bis-enones antiinflammatory compounds

Cytokinetics studies SB-743921 for NHL

PhG-alpha1 delays establishment and growth of colorectal cancer tumors in mice

Positive results for CRx-170 in proof-of-concept asthma study

Schering AG Boards recommend acceptance of Bayer offer

Isis licenses HIV inhibitor ISIS-5320 to ImQuest

Technosphere Insulin System improves HbA1c in phase II study

Schering-Plough updates status of phase II study of SCH-503034

Chiron shareholders approve acquisition by Novartis

Nonapprovable letter for Hexvix NDA

New compound class from Trubion Pharmaceuticals for B-cell chronic lymphocytic leukemias

PRX-08066 reduces systolic pulmonary blood pressure in study

Antitumor efficacy of new CD40 agonist antibody

Vesicare approved as first drug for overactive bladder in Japan

Funguard approved for use in children in Japan

Chugai seeks Japanese approval for Avastin in colorectal cancer

Japanese approval for Cetrotide for premature ovulation

New treatments for cancer covered in recent patents

Zometa receives new approval in Japan

AmBisome receives Japanese approval

Feron approved in Japan for compensatory cirrhosis C

Japanese approval for Nu-Lotan in diabetic nephropathy

HIV integrase inhibitors claimed in recent Pfizer patent

Novel cathepsin K inhibitor as a potential antiresorptive agent to treat osteoporosis

Synthesis and in vitro evaluation of new potent GAR Tfase inhibitor

Multinational phase III study shows positive results for panitumumab in metastatic colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...